07.08.20

Palatin Technologies Announces Reinitiation of Enrollment of Phase 2 Study With PL9643 for the Treatment of Dry Eye Disease

Source: Palatin Technologies

06.04.20

Aldeyra Therapeutics Reaches Agreement With FDA for Use of RASP as Dry Eye Disease Sign

Source: Aldeyra Therapeutics, Inc.

05.28.20

New Alcon Program Aims to Help ECPs Tap Into Opportunities in the Dry Eye Market Amid COVID-19 Crisis

Source: Alcon

05.26.20

Kala Pharmaceuticals Files New Drug Application to FDA for Eysuvis for Dry Eye Disease

Source: Kala Pharmaceuticals

05.18.20

Sight Sciences Announces Positive Clinical Results From Trial Evaluating TearCare for the Treatment of Dry Eye Disease

Source: Sight Sciences

05.12.20

Ocular Therapeutix Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI For Treatment of Dry Eye Disease

Source: Ocular Therapeutix

05.11.20

Oyster Point Announces Results of Phase 3 Trial of OC-01 Nasal Spray for Treatment of Signs and Symptoms of Dry Eye Disease

Source: Oyster Point Pharma

05.04.20

Kala Pharmaceuticals Resubmits NDA for Eysuvis for Dry Eye Disease

Source: Kala Pharmaceuticals

04.27.20

I-MED Pharma Gains Health Canada Approval For E>Eye Laser

Source: I-MED Pharma

04.08.20

Nicox Outlines Plans to Progress NCX 4251 into Phase 2b Trial Following Positive Meeting with FDA

Source: Nicox

View more stories